Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2018 June;43(2) > Minerva Endocrinologica 2018 June;43(2):212-20

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Endocrinologica 2018 June;43(2):212-20

DOI: 10.23736/S0391-1977.17.02745-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Diagnosis and management of Zollinger-Ellison syndrome in 2018

Claudio DE ANGELIS , Pablo CORTEGOSO VALDIVIA, Ludovica VENEZIA, Mauro BRUNO, Rinaldo PELLICANO

Department of Gastroenterology and Digestive Endoscopy, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy


PDF


Zollinger-Ellison syndrome (ZES) is a clinical syndrome characterized by gastric acid hypersecretion due to the ectopic secretion of gastrin by a gastrinoma, a neuroendocrine tumor (NET) which mostly develops in the duodenum and in the pancreas. This syndrome was first described by Zollinger and Ellison in 1964; if left untreated, ZES can lead to multiple complications mainly due to gastric hypersecretion and some patients can suffer from the complications of an advanced metastatic disease. Although its clinical features are considered typical, the diagnosis of ZES is often challenging for the clinician. A previous review was published in 2005 by our group, but in 12 years many things have changed: the diagnostic tools have been improved and many different therapeutical options are now available.


KEY WORDS: Neuroendocrine tumors - Gastrinoma - Zollinger-Ellison syndrome

top of page